Greenwich LifeSciences, Inc. GLSI 深 滬
已收盤 05-22 16:00:00 美东时间
27.65
+0.460
+1.69%
華盛通- 最 高28.78
- 今 開27.22
- 成交量 7.84万股
- 最 低 27.22
- 昨 收 27.19
- 總市值 3.83亿
- 52周最高 34.10
- 市盈率 靜 --
- 換手率 0.57%
- 52周最低 7.78
- 委 比 -97.33%
- 總股本 1385.45万
- 歷史最高 158.07
- 量 比 0.67
- 振 幅 5.74%
- 歷史最低 3.262
- 每 手 1
- 風險率 7.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Greenwich LifeSciences Receives Nasdaq Noncompliance Notice
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated
05-23 04:31
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Greenwich LifeSciences, Inc. received a notice from Nasdaq regarding non-compliance with listing rules due to the delay in filing its Q1 2026 10-Q report. The notice does not affect the trading of its common stock on Nasdaq. The company is focused on developing GP2, an immunotherapy for breast cancer recurrence prevention, and is conducting the Phase III FLAMINGO-01 trial.
05-22 20:30
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
04-22 17:31
Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
04-20 18:10
Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
04-07 18:04
Greenwich LifeSciences says new patent claims could double GLSI-100 market to 88,000 patients/year
Greenwich LifeSciences says new patent claims could double GLSI-100 market to 88,000 patients/year Greenwich Lifesciences disclosed new patent claims tied to already presented open-label data from Phase III FLAMINGO-01 for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Cla
04-07 18:03
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - Wall Street's main indexes were set to open lower on
03-19 21:15
BUZZ-Greenwich LifeSciences rises after expanding late‑stage breast cancer trial
BUZZ-Greenwich LifeSciences rises after expanding late‑stage breast cancer trial ** Shares of biotech firm Greenwich LifeSciences GLSI.O rise about 1.1% to $27 premarket ** Co says it has expanded its late‑stage trial of GLSI‑100, an experimental treatment aimed at preventing breast cancer recurrenc
03-19 18:50
